Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

Previous studies have shown that approximately 40% of patients with myelodysplastic syndrome (MDS) and anaemia respond to treatment with human recombinant granulocyte‐CSF (G‐CSF) plus erythropoietin (epo). The present study was designed to investigate pre‐treatment variables for their ability to pre...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1997-11, Vol.99 (2), p.344-351
Main Authors: Hellström‐Lindberg, Eva, Negrin, Robert, Stein, Richard, Krantz, Sanford, Lindberg, Greger, Vardiman, James, ÖSt, ÅKe, Greenberg, Peter
Format: Article
Language:English
Subjects:
Aged
Anemia - blood
Anemia - therapy
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
cytokines
Drug Therapy, Combination
erythropoiesis
erythropoietin
Erythropoietin - adverse effects
Erythropoietin - therapeutic use
Female
Forecasting
Granulocyte Colony-Stimulating Factor - adverse effects
Granulocyte Colony-Stimulating Factor - therapeutic use
G‐CSF
Humans
Leukocyte Count
Male
Medical sciences
Medicin och hälsovetenskap
Multivariate Analysis
myelodysplastic syndromes
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - therapy
Neutrophils
Pharmacology. Drug treatments
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies have shown that approximately 40% of patients with myelodysplastic syndrome (MDS) and anaemia respond to treatment with human recombinant granulocyte‐CSF (G‐CSF) plus erythropoietin (epo). The present study was designed to investigate pre‐treatment variables for their ability to predict erythroid responses to this treatment. 98 patients with MDS (30 RA, 31 RARS, 32 RAEB, five RAEB‐t) were treated with a combination of G‐CSF (0.3–3.0 μg/kg/d, s.c.) and epo (60–300 U/kg/d, s.c.) for at least 10 weeks. Minimum criteria for erythroid response was a 100% reduction of red blood cell (RBC) transfusion need or an increase in haemoglobin level of  1.5 g/dl. 35 patients (36%) showed responses to treatment. Medium duration of response was 11–24 months. In multivariate analysis, serum erythropoietin levels and initial RBC‐transfusion need retained high statistical significance (P 
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1997.4013211.x